Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Felbamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Felbamate SCHEMBL2946508 | 1.00 | CYP1A2 (1.00) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| Felbamate SCHEMBL17597519 | 0.98 | CYP1A2 (0.96) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| Felbamate SCHEMBL7153063 | 0.98 | CYP1A2 (0.96) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| Felbamate SCHEMBL1049127 | 0.93 | CYP1A2 (0.86) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8392182 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8392180 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8056124 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL14979788 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8089944 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL7775772 | 0.91 | CYP1A2 (0.83) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11949 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115231-A1 | TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS | SPINALCYTE LLC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092932-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER | THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| WO-1996036314-A2 | METHOD FOR DRUG DELIVERY TO THE PULMONARY SYSTEM | PHARMACEUTICAL DISCOVERY CORPORATION (US) | 1996-11-21 | — | — | WO | claimed |
| EP-0491094-B1 | Felbamate for treating Lennox-Gastaut syndrome | CARTER WALLACE (US) | 1996-09-11 | — | — | EP | claimed |
| US-5503852-A | CYCLODIMERIZATION OF AMINO ACIDS, PRECIPITATION OF MICROPARTICLES; FOR ENCAPSULATING DRUGS | PHARMACEUTICAL DISCOVERY CORPORATION (US) | 1996-04-02 | — | — | US | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995029665-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1995-11-09 | — | — | WO | claimed |
| WO-1994027941-A1 | PROCESS FOR PREPARING FELBAMATE AND INTERMEDIATES THERETO | AVONDALE CHEMICAL COMPANY (IE) | 1994-12-08 | — | — | WO | claimed |
| CN-1092759-A | The method for preparing felbamate and its intermediate | AVONDALE CHEM CORP (IE) | 1994-09-28 | — | — | CN | claimed |
| WO-1994006737-A1 | PROCESS FOR PREPARING FELBAMATE, 2-PHENYL-1,3-PROPANEDIOL AND INTERMEDIATES | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| EP-0413064-B1 | PREPARATION OF 2-PHENYL-1, 3-PROPANE DIOL AND ITS DICARBAMATE | CARTER-WALLACE INC. (US) | 1993-07-14 | — | — | EP | claimed |
| EP-0491094-A1 | Felbamate for treating Lennox-Gastaut syndrome | CARTER-WALLACE, INC. (US) | 1992-06-24 | — | — | EP | claimed |